Abstract
Premenstrual disorders are characterized by the cyclical recurrence of mood changes and physical symptoms beginning in the luteal phase of the menstrual cycle and improving following menstruation. Diagnostic and management principles for PMS were established by the American College of Obstetrics and Gynecologists (ACOG), while the more severe Premenstrual Dysphoric Disorder has diagnostic criteria found in the Diagnostic and Statistical Methods of Mental Disorders, Fifth Edition (DSM-V). Establishing a diagnosis of PMS/PMDD requires the daily recording of symptoms for at least two menstrual cycles. A key aspect of diagnosis includes ruling out mood disorders and other medical conditions. Information surrounding pathophysiology is continually evolving, with current research focused on abnormalities in ovarian sex steroid metabolites that act as neuromodulators. A trial of conservative management is appropriate in some scenarios, but first-line pharmacologic therapy including combined oral contraceptives and selective serotonin reuptake inhibitors, is highly effective.
Similar content being viewed by others
References
ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin: No 15; premenstrual syndrome. Obstet Gynecol. 2000;95(4):1–9.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
Craner JR, Sigmon ST, McGillicuddy ML. Does a disconnect occur between research and practice for premenstrual dysphoric disorder (PMDD) diagnostic procedures? Women Health. 2014;54(3):232–44.
de Wit AE, de Vries YA, de Boer MK, et al. Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials. Am J Obstet Gynecol. 2021;225(6):624–33.
Eisenlohr-Moul T, Divine M, Schmalenberger K, et al. Prevalence of lifetime self-injurious thoughts and behaviors in a global sample of 599 patients reporting prospectively confirmed diagnosis with premenstrual dysphoric disorder. BMC Psychiatry. 2022;22(1):199.
Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006;9(1):41–9.
Frank RT. The hormonal causes of premenstrual tension. Arch Neurol Psychiatr. 1931;26:1053–7.
Gastaldon C, Solmi M, Correll CU, Barbui C, Schoretsanitis G. Risk factors of postpartum depression and depressive symptoms: umbrella review of current evidence from systematic reviews and meta-analyses of observational studies. Br J Psychiatry. 2022;221:1–12.
Gehlert S, Song IH, Chang CH, Hartlage SA. The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol Med. 2009;39(1):129–36.
Greene R, Dalton K. The premenstrual syndrome. Br Med J. 1953;1:1007–14.
Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology. 2003;28(Suppl 3):55–99.
Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder-clinical procedures and research perspectives. Gynecol Endocrinol. 2004;19(6):320–34.
Halbreich U, O’Brien PM, Eriksson E, Backstrom T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs. 2006;20:523–47.
Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol Stress. 2020;12:100213.
Hunter MS, Ussher JM, Browne SJ, Cariss M, Jelley R, Katz M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol. 2002;23:193–9.
Lustyk MK, Gerrish WG, Shaver S, Keys SI. Cognitive behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Women’s Ment Health. 2009;12:85–96.
Marjoribanks J, Brown J, O’Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;6:CD001396.
Prior JC, Vigna Y, Sciarretta D, Alojado N, Schulzer M. Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Fertil Steril. 1987;47:402–8.
Rapkin AJ, Lewis EI. Treatment of premenstrual dysphoric disorder. Womens Health (Lond). 2013;9(6):537–56
Sayegh R, Schiff I, Wurtman J, Spirers P, McDermott J, Wurtman R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol. 1995;86(4 pt 1):520–682.
Schmidt PJ, Martinez PE, Nieman LK, et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry. 2017;174(10):980–9.
Steinberg EM, Cardoso GM, Martinez PE, et al. Rapid response to fluoxetine in women with premenstrual dysphoric disorder. Depress Anxiety. 2012;29:531–40.
Steiner M, Li T. Luteal phase and symptom-onset dosing of SSRIs/SNRIs in the treatment of premenstrual dysphoria: clinical evidence and rationale. CNS Drugs. 2013;27:583–9.
Taylor JW. Plasma progesterone, oestradiol 17 beta and premenstrual symptoms. Acta Psychiatr Scand. 1979;60:76.
Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome; effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol. 1998;179:444–52.
Vishnupriya R, Rajarajeswaram P. Effects of aerobic exercise at different intensities in premenstrual syndrome. J Obstet Gynaecol India. 2011;61:675–82.
Wyatt KM, Dimmock PW, Frischer M, et al. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG. 2004;111:585–93.
Yonkers KA, Kornstein SG, Gueorguieva R, et al. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:1037–44.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Anderson, Z. (2023). Diagnosis and Treatment of Premenstrual Syndrome. In: Shoupe, D. (eds) Handbook of Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-319-17002-2_33-2
Download citation
DOI: https://doi.org/10.1007/978-3-319-17002-2_33-2
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17002-2
Online ISBN: 978-3-319-17002-2
eBook Packages: Springer Reference MedicineReference Module Medicine